Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Jeroen N Hiltermann

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Cancer Letters|October 27, 2010
Targeting apoptosis pathways in lung cancerMilind M Pore, T Jeroen N Hiltermann, Frank A E Kruyt
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|June 3, 2020
Prioritisation of treatment goals among older patients with non-curable cancer: the OPTion randomised controlled trial in Dutch primary careMariken E Stegmann, Daan Brandenbarg, An Kl Reyners, et al.
Translational Lung Cancer Research|March 11, 2026
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysisErick Suazo-Zepeda, Marjolein A Heuvelmans, Douwe Postmus, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 13, 2019
[Correspondence between primary and secondary healthcare providers about patients with cancer; how can it be improved?]Mariken E Stegmann, Jiska M Meijer, Janine Nuver, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2021
A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic markerWin Sen Heng, Milind Pore, Coby Meijer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2026
Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2)Esin Aysel Kandemir, Julia Roeper, Lena Ansmann, et al.
Journal for Immunotherapy of Cancer|July 12, 2019
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitorsMenno Tamminga, Sanne de Wit, T Jeroen N Hiltermann, et al.
Translational Lung Cancer Research|February 4, 2020
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapyMenno Tamminga, Sanne de Wit, Ed Schuuring, et al.
Cancers|October 13, 2018
Classification of Cells in CTC-Enriched Samples by Advanced Image AnalysisSanne de Wit, Leonie L Zeune, T Jeroen N Hiltermann, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2025
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based modelRianne D W Vaes, Francesco Cortiula, Shaowen Lyu, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Cancer Letters|October 27, 2010
Targeting apoptosis pathways in lung cancerMilind M Pore, T Jeroen N Hiltermann, Frank A E Kruyt
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|June 3, 2020
Prioritisation of treatment goals among older patients with non-curable cancer: the OPTion randomised controlled trial in Dutch primary careMariken E Stegmann, Daan Brandenbarg, An Kl Reyners, et al.
Translational Lung Cancer Research|March 11, 2026
Association of CT-assessed sarcopenia and the development of immune-related adverse events and overall survival: a multistate survival analysisErick Suazo-Zepeda, Marjolein A Heuvelmans, Douwe Postmus, et al.
Nederlands Tijdschrift Voor Geneeskunde|June 13, 2019
[Correspondence between primary and secondary healthcare providers about patients with cancer; how can it be improved?]Mariken E Stegmann, Jiska M Meijer, Janine Nuver, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2021
A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic markerWin Sen Heng, Milind Pore, Coby Meijer, et al.
Lung Cancer (Amsterdam, Netherlands)|April 9, 2026
Multidisciplinary tumor boards (MTBs) and survival Outcomes: Adherence to MTB recommendations in patients with lung cancer treated at two European cancer centers (AdThera-2)Esin Aysel Kandemir, Julia Roeper, Lena Ansmann, et al.
Journal for Immunotherapy of Cancer|July 12, 2019
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitorsMenno Tamminga, Sanne de Wit, T Jeroen N Hiltermann, et al.
Translational Lung Cancer Research|February 4, 2020
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapyMenno Tamminga, Sanne de Wit, Ed Schuuring, et al.
Cancers|October 13, 2018
Classification of Cells in CTC-Enriched Samples by Advanced Image AnalysisSanne de Wit, Leonie L Zeune, T Jeroen N Hiltermann, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2025
Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based modelRianne D W Vaes, Francesco Cortiula, Shaowen Lyu, et al.
Pageof 6